Abstract
Determining whether a given animal or human tumor possesses antigens capable of evoking a specific antitumor immune response is essential before a rational attempt can be made to treat the tumor by a therapeutic modality designed to augment specific antitumor immunity. The role of the experimental tumor immunologists is to obtain detailed information about the immunogenicity of animal tumors and about the antitumor immune response they evoke, with a view to supplying the clinical oncologist with knowledge about the type of immune response that needs to be boosted. Regardless of whether or not animal tumors are suitable models of the human disease, the fact is that animal and human tumors have a lot in common, including the capacity to grow progressively in their hosts. Therefore, even though an animal tumor may possess tumor-specific antigens, it is not destroyed by specific or nonspecific host defense mechanisms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Foley, E. J., 1953, Antigenic properties of methylcholanthrene-induced tumors in mice at the strain of origin, Cancer Res. 13:835–837.
Old, L. J., Boyse, E. A., Clarke, D. A., and Carswell, E. A., 1962, Antigenic properties of chemicallyinduced tumors, Ann. N.Y. Acad. Sci. 101:80–106.
Sjogren, H. O., 1965, Transplantation methods as a tool for detection of tumor-specific antigens, Prog. Exp. Tumor Res. 6:289–322.
Klein, G., 1966, Tumor antigens, Annu Rev. Microbiol. 20:223–252.
Hellstrom, K. E., and Hellstrom, I., 1969, Cellular immunity against tumor antigens, Adv. Cancer Res. 12:167–223.
Tuttle, R. L., and North, R. J., 1976, Mechanisms of antitumor action of Corynebacterium parvum: Replicating short-lived T cells as the mediators of potentiated tumor-specific immunity, J. Reticuloendothel. Soc. 20:209–216.
Burton, R. C., Chism, S. E., and Warner, N. L., 1978, In vitro induction and expression of T cell immunity to tumor-associated antigens, Contemp. Top. Immunobiol. 8:69–106.
Greenberg, P. D., Kern, D. E., and Cheever, M. A., 1985, Therapy of disseminated murine leukemia with cyclophosphamide and immune Ly-l+,2- T cells: Tumor eradication does not require participation of cytotoxic T cells, J. Exp. Med. 161:1122–1134.
Bhan, A. K., Perry, L. L., Cantor, H., McCluskey, R. T., Benacerraf, B., and Greene, M. I., 1981, The role of T cell sets in rejection of a methylcholanthrene-induced sarcoma (S1509a) in syngeneic mice, Am. J. Pathol. 102:20–27.
Loveland, B. E., Hogarth, P. M., Ceredig, R., and McKenzie, I. F. C., 1981, Cells mediating skin graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection, J. Exp. Med. 153:1044–1057.
Lukacher, A. E., Morrison, L. A., Braciale, V. L., Malissen, B., and Braciale, T. J., 1985, Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones, J. Exp. Med. 162:172–187.
Golding, H., Munitz, T. I., and Singer, A., 1985, Characterization of antigen-specific, la-restricted, L3T4+ cytolytic T lymphocytes and assessment of thymic influence on their self specificity, J. Exp. Med. 162:943–961.
Gorelik, E., 1983, Concomitant tumor immunity, Adv. Cancer Res. 39:71–120.
North, R. J., and Kirstein, D. P., 1977, T cell-mediated concomitant immunity to syngeneic tumors: Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites, J. Exp. Med. 145:275–292.
Bast, R. C., Bast, B. S., and Rapp, H. J., Critical review of previously reported animal studies of tumor immunotherapy with non-specific immunostimulants, 1976, Ann. N.Y. Acad. Sci. 277:60–92.
Vaage, J., 1971, Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue, Cancer Res. 31:1655–1662.
Takai, F., Levy, J. G., and Kilburn, D. G., 1976, In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor bearing mice, J. Immunol. 116:288–293.
Tuttle, R. L., Knick, V. C., Stopford, C. R., and Wolberg, G., 1983, In vivo and in vitro antitumor activity expressed by cells of concomitant immune mice, Cancer Res. 43:2600–2605.
North, R. J., and Dye, E. S., 1985, Ly-1+2- suppressor T cells down-regulate the generation of Ly 1+2- effector T cells, Immunology 53:47–56.
North, R. J., and Bursuker, I., 1984, The generation and decay of the immune response to a progressive fibrosarcoma: Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells, J. Exp. Med. 159:1295–1311.
North, R. J., 1984, The therapeutic significance of concomitant antitumor immunity: Ly-1-2+ T cells from mice with a progressive tumor cause regression of an established tumor in 7-irradiated recipients, Cancer Immunol. Immunother. 18:69–74.
Dye, E. S., 1986, The antimetastatic function of concomitant immunity. II. Evidence that the genration of Ly-1+2+ effector T cells temporarily causes destruction of already disseminated tumor cells, J. Immunol. 136:1510–1515.
Greene, M. I., 1980, The genetic and cellular basis of regulation of the immune response to tumor antigens, Contemp. Top. Immunobiol. 11:81–116.
Hawrylko, E., 1982, Tumor bearer T cells suppress BCG-potentiated antitumor responses. 1. Requirements for their effectors, Cell. Immunol. 66:121–138.
Hawrylko, E., Mele, C. A., and Stutman, O., 1982, Tumor bearer T cells suppress BCG-potentiated antitumor responses. II. Characteristics of the efferent phase suppressor, Cell. Immunol. 66:139–151.
Berendt, M. J., and North, R. J., 1980, T cell-mediated immunosuppression of antitumor immunity: An explanation for progressive growth of an immunogenic tumor, J. Exp. Med. 151:69–80.
Dye, E. S., and North, R. J., 1981, T cell mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases, J. Exp. Med. 154:1033–1042.
Bonventre, P. F., Nockol, A. D., Ball, E. J., Michael, J. G., and Bubel, H. C., 1982, Development of protective immunity against bacterial and viral infections in tumor-bearing mice is coincident with suppression, J. Reticuloendothel. Soc. 32:25–34.
North, R. J., 1982, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on the elimination of tumor-induced suppressor T cells, J. Exp. Med. 55:1063–1074.
North, R. J., 1984, γ-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells, Cancer Immunol. Immunother. 16:175–181.
Dye, E. S., and North, R. J., 1984, Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors, J. Leukocyte Biol. 36:27–38.
Bursuker, I., and North, R. J., 1985, Suppression of generation of concomitant immunity by passively transferred suppressor T cells from tumor-bearing donors, Cancer Immunol. Immunother. 19:215–218.
Hellstrom, K. E., Hellstrom, I., Kant, J. A., and Temerius, J. D., 1978, Regression and inhibition of sarcoma growth by interference with a radiosensitive T cell population, J. Exp. Med. 148:799–804.
Frost, P., Prete, P., and Kerbel, R., 1982, Abrogation of the in vitro generation of the cytotoxic T cell response to a murine tumor: The role of suppressor cells, Int. J. Cancer 30:211–217.
Mills, C. D., and North, R. J., 1983, Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient: Inhibition by suppressor T cells, J. Exp. Med. 157:1448–1460.
Dye, E. S., and North, R. J., 1984, Adoptive immunization against an established tumor with cytolytic versus memory T cells: Immediative versus delayed onset of regression, Transplantation 37:600–605.
Hall, B. M., Jelbart, M. E., Gurley, K. E., and Dorsch, S. E., 1985, Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine: Mediation of suppression by T helper/inducer cells, J. Exp. Med. 162:1683–1694.
Mullen, C. A., Urban, J. L, VanWaes, C., Rowley, D. A., and Schreiber, H., 1985, Multiple cancers: Tumor burden permits the outgrowth of other cancers, J. Exp. Med. 162:1665–1682.
DiGiacomo, A., and North, R. J., 1986, T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity, J. Exp. Med. 164:1179–1192.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
North, R.J., DiGiacomo, A., Dye, E.S. (1987). The Generation and Down-Regulation of the Immune Response to Progressive Tumors. In: Greene, M.I., Hamaoka, T. (eds) Development and Recognition of the Transformed Cell. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1925-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1925-2_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9070-4
Online ISBN: 978-1-4613-1925-2
eBook Packages: Springer Book Archive